Quality & complianceOfficial

Fixopost single-dose eye drops face Danish supply problems into December

🇩🇰 DKMA · Wed 28 Oct 2026

The Danish Medicines Agency says Thea Nordic AB's latanoprost/timolol eye drops are affected by production problems, with disruption expected from late September to early December 2026.

The Danish Medicines Agency (DKMA) has reported current supply problems with Fixopost 50 micrograms/ml + 5 mg/ml eye drops, solution, in single-dose containers. The marketing company is Thea Nordic AB.

The notice was first published on 22 September 2026 and updated on 28 October 2026. DKMA gives the cause as production problems and the expected period of disruption as the end of September to the start of December 2026.

The product contains the active substances latanoprost and timolol and carries ATC code S01ED51. The notice does not name alternative products or describe any measures to maintain supply.

DKMA directs questions about the current status to the company. The notice sits in the agency's supply notifications for human medicines.

What it means for your team

  • Supply-chain teams should check Danish stock of the single-dose presentation against the stated window of late September to early December 2026.
  • Because the notice names no alternatives, prescribers and pharmacies may need to consult the company or DKMA's supply pages on options.
  • Teams should ask Thea Nordic AB for the latest status, as DKMA refers such queries to the company.
  • Quality teams may want to track the 'production problems' cause, which the notice does not detail.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →